A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
מצבים רפואיים
Pompe Disease (Late-onset) · Pompe Disease Late-Onset · LOPD
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
Barrow Neurological Institute, Phoenix, Arizona, United States
Contact: Principal Investigator (Shafeeq Ladha, MD)University of California, Irvine (UCI), Irvine, California, United States
Contact: Principal Investigator (Tahseen Mozaffar, MD)Stanford Neuroscience Health Center, Palo Alto, California, United States
Contact: Principal Investigator (John Day, MD, PhD)NYU Langone, New York, New York, United States
Contact: Principal Investigator (Nicolas Abreu, MD)Duke University, Durham, North Carolina, United States
Contact: Principal Investigator (Natalie Katz, MD, PhD)Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (Paul McIntosh, MD)University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Paula Clemens, MD)University of Texas Southwest Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Markey McNutt, MD, PhD) · geneticsresearch@utsouthwestern.edu · 214-645-7411Contact: Principal Investigator (Markey McNutt, MD, PhD)Virginia Commonwealth University (VCU), Richmond, Virginia, United States
Contact: Principal Investigator (Susan Sparks, MD, PhD)